1. Home
  2. APM vs SONN Comparison

APM vs SONN Comparison

Compare APM & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APM
  • SONN
  • Stock Information
  • Founded
  • APM 2010
  • SONN N/A
  • Country
  • APM United Kingdom
  • SONN United States
  • Employees
  • APM N/A
  • SONN N/A
  • Industry
  • APM Biotechnology: Pharmaceutical Preparations
  • SONN Biotechnology: Pharmaceutical Preparations
  • Sector
  • APM Health Care
  • SONN Health Care
  • Exchange
  • APM Nasdaq
  • SONN Nasdaq
  • Market Cap
  • APM 18.9M
  • SONN 21.4M
  • IPO Year
  • APM 2018
  • SONN N/A
  • Fundamental
  • Price
  • APM N/A
  • SONN $5.44
  • Analyst Decision
  • APM
  • SONN Strong Buy
  • Analyst Count
  • APM 0
  • SONN 1
  • Target Price
  • APM N/A
  • SONN $20.00
  • AVG Volume (30 Days)
  • APM 434.9K
  • SONN 1.7M
  • Earning Date
  • APM 04-30-2025
  • SONN 08-13-2025
  • Dividend Yield
  • APM N/A
  • SONN N/A
  • EPS Growth
  • APM N/A
  • SONN N/A
  • EPS
  • APM N/A
  • SONN N/A
  • Revenue
  • APM N/A
  • SONN $1,000,000.00
  • Revenue This Year
  • APM N/A
  • SONN $5,376.22
  • Revenue Next Year
  • APM N/A
  • SONN N/A
  • P/E Ratio
  • APM N/A
  • SONN N/A
  • Revenue Growth
  • APM N/A
  • SONN 1689.52
  • 52 Week Low
  • APM $0.46
  • SONN $1.08
  • 52 Week High
  • APM $7.49
  • SONN $19.30
  • Technical
  • Relative Strength Index (RSI)
  • APM 62.63
  • SONN 53.42
  • Support Level
  • APM $1.74
  • SONN $4.25
  • Resistance Level
  • APM $2.50
  • SONN $6.19
  • Average True Range (ATR)
  • APM 0.17
  • SONN 0.85
  • MACD
  • APM 0.05
  • SONN -0.09
  • Stochastic Oscillator
  • APM 77.22
  • SONN 33.06

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

About SONN Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Share on Social Networks: